Cerluten vs HLDF-6

CNS-targeted peptide complex that modulates neuronal gene expression. Shown in Russian clinical studies to improve memory consolidation, attention, and protect against neurodegeneration.

Cerluten is a synthetic short peptide classified as a Khavinson-class bioregulator targeted at cerebral and central nervous system tissue, investigated for neuroprotective and anti-aging properties in neuronal cell populations through proposed gene expression regulatory mechanisms. Like other Khavinson bioregulator peptides, cerluten is proposed to reach target neuronal cells via amino acid transporter uptake — including proton-coupled oligopeptide transporters (POT) and large amino acid transporters (LAT) — and to modulate transcriptional activity in aging or damaged neural tissue. Published research on Khavinson-class ultrashort peptides has characterized intracellular transport via POT and LAT carriers and demonstrated gene expression regulatory effects across multiple tissue types, providing the class-level mechanistic framework within which cerluten's neuronal effects are proposed. Cerluten has no FDA approval or regulatory approval in any major Western jurisdiction; evidence derives from Khavinson-series preclinical and class-level studies with no independent clinical trials published in Western-indexed journals. Cerluten dosing and respiratory applications Cerluten is classified as a bronchial tissue bioregulator in the Khavinson peptide research tradition, proposed to act on bronchial epithelial cells via amino acid transporter uptake and modulate gene expression related to respiratory tissue maintenance and oxidative stress response in aging airways. Preclinical and observational research in Eastern European clinical settings has examined cerluten in contexts of chronic bronchitis, age-related decline in respiratory function, and COPD support, with proposed mechanisms including anti-inflammatory gene regulation and bronchial epithelial cell cytoprotection. Standard Khavinson-class dosing protocols use oral capsule formulations in 10–20 day cycles at 5–10mg per cycle (divided doses), followed by rest intervals — consistent with the gene-regulatory rather than continuous-receptor-occupancy mechanism proposed for this peptide class. Independent peer-reviewed clinical trial evidence specific to cerluten is limited; efficacy data comes primarily from Khavinson Institute publications and observational reports. Cerluten is available from specialty Eastern European supplement and peptide vendors and is not approved by the FDA or EMA as a pharmaceutical. It is distinct from Chonluten, which targets lung parenchyma rather than bronchial epithelial tissue.

Modulates cholinergic neurotransmission. Reduces amyloid-β toxicity and protects against oxidative stress-induced neuronal damage. May enhance memory consolidation via acetylcholine pathway upregulation.

HLDF-6 (human leukemia differentiation factor hexapeptide; TGENHR) is a synthetic hexapeptide derived from a sequence of the HLDF protein, investigated in preclinical models for neuroprotective properties in conditions including Alzheimer's disease and Parkinson's disease, where it is proposed to reduce neuroinflammation, protect against beta-amyloid toxicity, and attenuate dopaminergic neuron loss. HLDF-6 is proposed to modulate inflammatory cytokines and oxidative stress pathways, with potential effects on acetylcholinesterase activity; preclinical animal studies in transgenic Alzheimer's models and MPTP-induced Parkinson's models suggest cognitive-protective properties at the cellular and behavioral level. No published human clinical trials, pharmacokinetic studies, or safety evaluations of HLDF-6 administration have been indexed in PubMed; the entirety of its evidence base consists of rodent and cell-based studies, and no regulatory authority has evaluated or approved HLDF-6 for any human indication. HLDF-6 has no FDA approval or regulatory approval in any jurisdiction; it is a neuroprotective research compound with a defined mechanistic hypothesis and an exclusively preclinical evidence base, and the translation of its animal model findings to human therapeutic outcomes has not been investigated.